Seminars in Oncology
Volume 34, Issue 4 , Pages 347-353 , August 2007

Cytotoxic Therapy for Advanced Pancreatic Adenocarcinoma

  • Eileen M. O’Reilly

      Affiliations

    • Corresponding Author InformationAddress correspondence to Eileen M. O’Reilly, MD, Department of Medicine, Gastrointestinal Oncology Solid Tumor Service, Memorial Sloan-Kettering Cancer Center, Box 324, 1275 York Ave, New York, NY 10021.
    • ,
  • Ghassan K. Abou-Alfa

References 

  1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. Ca Cancer J Clin. 2007;57:43–66
  2. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 1997;15:2403–2413
  3. Bruckner HW, Storch JA, Brown JC, et al. Phase-II trial of combination chemotherapy for pancreatic-cancer with 5-fluorouracil, mitomycin-c, and hexamethylmelamine. Oncology. 1983;40:165–169
  4. Cascinu S, Fedeli A, Fedeli SL, et al. 5-Fluorouracil, leucovorin and interferon-alpha 2b in advanced pancreatic-cancer—A pilot study. Ann Oncol. 1993;4:83–84
  5. Raderer M, Kornek GV, Hejna MH, et al. Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: A phase II study. Ann Oncol. 1997;8:797–799
  6. Wiggans RG, Woolley PV, Macdonald JS, et al. Phase-II trial of streptozotocin, mitomycin-c and 5-fluorouracil (SMF) in treatment of advanced pancreatic cancer. Cancer. 1978;41:387–391
  7. Fung MC, Ishiguru H, Takayama S, et al. Survival benefit of chemotherapy in advanced pancreatic cancer: A meta-analysis. J Clin Oncol. 2003;22:288s;288s
  8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer—A randomized controlled trial. JAMA. 2007;297:267–277
  9. Regine WF, Winter KW, Abrams R, et al. RTOG 9704 a phase III study of adjuvant pre and post chemoradiation (CRT) 5-FU vs. gemcitabine (G) for resected pancreatic adenocarcinoma. J Clin Oncol. 2006;24:180s;180s
  10. Plunkett W, Huang P, Xu YZ, et al. Gemcitabine—Metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995;22:3–10
  11. Tempero M, Plunkett W, van Haperen VR, et al. Randomized phase II comparison of dose-intense gemcitabine: Thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003;21:3402–3408
  12. Poplin E, Levy DE, Berlin J, et al. Phase III trial of gemcitabine (30-minute infusion) versus gemcitabine (fixed-dose-rate infusion [FDR]) versus gemcitabine plus oxaliplatin (GEMOX) in patients with advanced pancreatic cancer. J Clin Oncol. 2006;24:180s;180s, (E6201)
  13. Phase III randomised comparison of gemcitabine (GEM) versus gemcitabine plus capecitabine (GEM-CAP) in patients with advanced pancreatic cancer. Eur J Cancer Supplement. 2005;3:12
  14. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine (G) plus capecitabine (C) versus g alone in locally advanced or metastatic pancreatic cancer (A randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG)). J Clin Oncol. 2005;23:1092s;1092s
  15. Song HS, Do YR, Chang HM, et al. Capecitabine (X) plus gemcitabine (G) as first-line treatment in patients (pts) with locally advanced/metastatic pancreatic cancer: An open-label, multicenter phase II study. J Clin Oncol. 2005;23:343s;343s
  16. Stathopoulos GP, Syrigos K, Polyzos A, et al. Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: An intergroup, multicenter, phase II study. Ann Oncol. 2004;15:224–229
  17. Heinemann V, Wilke H, Mergenthaler HG, et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol. 2000;11:1399–1403
  18. Louvet C, Andre T, Lledo G, et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: Final results of a GERCOR multicenter phase II study. J Clin Oncol. 2002;20:1512–1518
  19. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: Results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23:3509–3516
  20. Louvet C, Hincke A, Labianca R, et al. Increased survival using platinum analog combined with gemcitabine as compared to gemcitabine single agent in advanced pancreatic cancer (APC): Pooled analysis of two randomised trials, the GERCOR/GISCAD Intergroup Study and a German Multicenter Study. J Clin Oncol. 2006;24:179s;179s
  21. Wagener DJT, Verdonk HER, Dirix LY, et al. Phase-II trial of Cpt-11 in patients with advanced pancreatic-cancer, an EORTC Early Clinical Trials Group study. Ann Oncol. 1995;6:129–132
  22. Sun FX, Tohgo A, Bouvet M, et al. Efficacy of camptothecin analog DX-8951f (exatecan mesylate) on human pancreatic cancer in an orthotopic metastatic model. Cancer Res. 2003;63:80–85
  23. Royce ME, Hoff PM, Dumas P, et al. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novel camptothecin analog. J Clin Oncol. 2001;19:1493–1500
  24. Lima CMR, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22:3776–3783
  25. Abou-Alfa GK, Letourneau R, Harker G, et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 2006;24:4441–4447
  26. Androulakis N, Kourousis C, Dimopoulos AM, et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: A multicenter phase II study. Ann Oncol. 1998;9:54
  27. Lenzi R, Yalcin S, Evans DB, et al. Phase II study of docetaxel in patients with pancreatic cancer previously untreated with cytotoxic chemotherapy. Cancer Invest. 2002;20:464–472
  28. Okada S, Sakata Y, Matsuno S, et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: A Japanese cooperative study. Br J Cancer. 1999;80:438–443
  29. Cascinu S, Gasparini G, Catalano V, et al. A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol. 1999;10:1377–1379
  30. Kulke MH, Niedzwiecki D, Tempero MA, et al. A randomized phase II study of gemcitabine/cisplatin, gemcitabine fixed dose rate infusion, gemcitabine/docetaxel, or gemcitabine/firinotecan in patients with metastatic pancreatic cancer. J Clin Oncol. 2004;22:316s;(CALGB 89904)
  31. Schneider BP, Ganjoo KN, Seitz DE, et al. Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study. Oncology. 2003;65:218–223
  32. Stathopoulos GP, Mavroudis D, Tsavaris N, et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: A phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol. 2001;12:101–103
  33. Lutz MP, Van Cutsem E, Wagener T, et al. Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: Randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group. J Clin Oncol. 2005;23:9250–9256
  34. Kindler HL. The pemetrexed/gemcitabine combination in pancreatic cancer. Cancer. 2002;95:928–932
  35. Giovannetti E, Mey V, Danesi R, et al. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res. 2004;10:2936–2943
  36. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol. 2005;16:1639–1645
  37. Fine RL, Fogelman DR, Schreibman S, et al. GTX chemotherapy for metastatic pancreatic cancer: Response, survival, and toxicity data. J Clin Oncol. 2004;22:380s
  38. Kozuch P, Grossbard ML, Barzdins A, et al. Irinotecan combined with gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (G-FLIP) is an effective and noncrossresistant treatment for chemotherapy refractory metastatic pancreatic cancer. Oncologist. 2001;6:488–495
  39. Cereda S, Mazza E, Passoni P, et al. PEFG salvage therapy inpatients with gemcitabine-resistant advanced pancreatic cancer (PC). Ann Oncol. 2006;17:58–59
  40. Reni M, Cereda S, Bonetto E, et al. Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol. 2007;59:361–367
  41. Reni M, Passoni P, Bonetto E, et al. Final results of a prospective trial of a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma. Oncology. 2005;68:239–245
  42. Reni M, Ferreri AJM, Panucci MG, et al. Significant improvement of response rate and survival with cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEF-G regimen) in metastatic pancreatic cancer. Eur J Cancer. 1999;35:S149
  43. Reni M, Cordio S, Milandri C, et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: A randomised controlled multicentre phase III trial. Lancet Oncol. 2005;6:369–376
  44. Cartwright TH, Cohn A, Varkey JA, et al. Phase II study of oral capecitabine in patients with advanced or metastatic pancreatic cancer. J Clin Oncol. 2002;20:160–164
  45. Burris HA, Rivkin S, Reynolds R, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist. 2005;10:183–190
  46. Jacobs AD, Burris HA, Rivkin S, et al. A randomized phase III study of rubitecan (ORA) vs. best choice (BC) in 409 patients with refractory pancreatic cancer report from a North-American multi-center study. J Clin Oncol. 2004;22:316s
  47. Briasoulis E, Pavlidis N, Terret C, et al. Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer (A phase II trial of the EORTC-New Drug Development Group). Eur J Cancer. 2003;39:2334–2340
  48. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer (A phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]). J Clin Oncol. 2005;23:1S
  49. Xie DR, Liang HL, Wang Y, et al. Meta-analysis on inoperable pancreatic cancer: A comparison between gemcitabine-based combination therapy and gemcitabine alone. World J Gastroenterol. 2006;12:6973–6981
  50. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol. 2002;20:3270–3275
  51. Riess H, Helm A, Niedergethmann M, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. J Clin Oncol. 2005;23:1092s
  52. Colucci G, Giuliani F, Gebbia V, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma—A prospective, randomized phase III study of the Gruppo Oncologico dell’Italia Meridionale. Cancer. 2002;94:902–910
  53. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol. 2006;24:3946–3952
  54. Ulrich-Pur H, Raderer M, Kornek GV, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer. 2003;88:1180–1184
  55. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology. 2004;67:93–97
  56. Tsavaris N, Kosmas C, Skopelitis H, et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. Invest New Drugs. 2005;23:369–375
  57. Oettle H, Pelzer U, Stieler J, et al. Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer. J Clin Oncol. 2005;23:315s;(CONKO 003)
  58. Papish SW, Ramanathan RK, Pincus J, et al. Patients rescued by crossover to rubitecan in phase III study of rubitecan capsules versus 5-FU in pancreatic cancer. J Clin Oncol. 2005;23:349s
  59. Demols A, Peeters M, Polus M, et al. Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: A phase II study. Br J Cancer. 2006;94:481–485
  60. Xiong HQ, Wolff RA, Hess KR, et al. A phase II trial of oxaliplatin plus capecitabine (Xelox) as second line therapy for patients with advanced pancreatic cancer. J Clin Oncol. 2006;24:207s
  61. Boeck S, Weigang-Kohler K, Fuchs M, et al. Second-line chemotherapy with pemetrexed after gemcitabine failure in patients with advanced pancreatic cancer: A multicenter phase II trial. Ann Oncol. 2007;18:745–751

PII: S0093-7754(07)00114-5

doi: 10.1053/j.seminoncol.2007.05.009

Seminars in Oncology
Volume 34, Issue 4 , Pages 347-353 , August 2007

Article Tools